#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Parkinson's disease Neutropenia Small for dates baby Acute lymphocytic leukaemia KBG syndrome Transitional cell carcinoma Metastatic malignant melanoma Brain injury Neoplasm malignant Pancreatic carcinoma Anaplastic thyroid cancer Iron overload Desmoplastic small round cell tumour Waldenstrom's macroglobulinaemia refractory Peritoneal neoplasm More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia recurrent – Basic Information Haemophilia B without inhibitors – Life with Disease Chordoma – Treatment Piriformis syndrome Synovial sarcoma recurrent – Life with Disease Carcinoid syndrome – Trials in Disease Angiosarcoma non-metastatic – Trials in Disease Synovial sarcoma metastatic – Basic Information Usher’s syndrome – Treatment Ocular melanoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trientine Dihydrochloride Amisulpride Obexelimab ALE1 Furosemide Ph. Eur. Gen1047 Arginine Hydrochloride Brexpiprazole CEFTAROLINE FOSAMIL Resiquimod Sulfate Cabozantinib Zongertinib Pyridoxine PIPOTIAZINE MB-CART2219.1 Domvanalimab Protease Nortriptyline Hydrochloride TAZAROTENE Vericiguat More therapies…

    Learn about Your Condition

    Anorexia nervosa Lung adenocarcinoma stage III Liver transplant rejection Burning mouth syndrome Malignant melanoma stage II Acute respiratory failure End stage renal disease Breast cancer female Infection Tendon rupture Invasive breast carcinoma Double hit lymphoma Hyperinsulinism Endometriosis Transplant rejection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Study on Murcidencel for Children, Adolescents, and Young Adults with High-Risk Progressive or Recurrent Metastatic Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Murcidencel
    Czechia

  • Study on the Safety and Effectiveness of Vidutolimod and Cemiplimab for Adults with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Vidutolimod
    • Cemiplimab
    France

  • Continued Regorafenib Treatment for Patients with Solid Tumors from Previous Bayer Studies

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Regorafenib
    France Spain

  • Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Bladder cancer
    • Gastric cancer
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria Denmark Finland France Germany Italy +3

  • Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Pertuzumab
    • Trastuzumab Emtansine
    Belgium France Poland Portugal Spain

  • Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Haematological malignancy
    • Neoplasm malignant
    Investigated Drugs:
    • Ociperlimab
    • Pamiparib
    • Tislelizumab
    France Italy Poland
Previous Page
1 … 12 13 14 15 16 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!